🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are escalating globally, with data suggesting over 82 million instances annually. Especially elevated rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs currently available.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance revealed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is employed against UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This milestone represents a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Testing Data and Worldwide Availability

Based on results released by a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which involves two antibiotics. The trial enrolled hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Doctors on the front lines have voiced hope. Access to a single-dose, oral treatment of this kind is seen as a "revolutionary step" for gonorrhoea control. This is considered vital to lessen the impact of the disease for patients and to halt the transmission of extremely resistant gonorrhoea globally.